Jade Biosciences

Jade Biosciences is developing a series of potential first-class therapies to redefine the treatment standards for patients with autoimmune diseases. Our potential first-class biologics pipeline was designed by Paragon Therapeutics, a company founded by leading healthcare investor Fairmount. Following Apogee Therapeutics, Spyre Therapeutics, and Oruka Therapeutics, Jade is the fourth company established by Paragon utilizing assets in the discovery stage.